Alternaria Allergy Shots: The Only Mold With Proven SCIT Evidence
Alternaria alternata allergy shots (SCIT) reduced combined symptom-medication scores by 63.5% at year 3 per Kuna 2011 JACI — the strongest mold-immunotherapy evidence in existence. Alternaria is the only fungal allergen with multiple DBPC-RCTs and the one sensitization independently linked to an adjusted OR of 189.5 for asthma-related respiratory arrest per O'Hollaren 1991 NEJM. Component testing with rAlt a 1 should confirm true sensitization before shots begin.
Alternaria Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to alternaria — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of alternaria allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of alternaria immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of alternaria extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for alternaria allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing alternaria extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription alternaria immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat alternaria allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Alternaria?
The biology, taxonomy, and clinical fingerprint of Alternaria — the foundation of how SCIT targets it.
Alternaria alternata conidia — muriform, dark brown, 20–60 µm. Detected in 25.5% of US bedroom dust samples (NHANES 2005–2006 Salo PM et al., JACI 2006).
- Scientific name
- Alternaria alternata
- Family
- PleosporaceaePleospora family (Ascomycota, Dothideomycetes)
- Type
- Outdoor dematiaceous mold — seasonal, with indoor penetration
- Native to
- Cosmopolitan; ubiquitous in soil, decaying vegetation, and agricultural environments worldwide
- Allergen proteins
- Alt a 1 (major) — unique 29–30 kDa beta-barrel homodimer; 80–100% IgE recognition in sensitized patientsAlt a 4 — protein disulfide isomerase, 22–42% IgE reactivityAlt a 6 — enolase, pan-fungal cross-reactive, 22% IgE reactivityAlt a 8 — mannitol dehydrogenase, 12.5–41% IgE reactivityAlt a 13 — glutathione-S-transferase, up to 82% IgE reactivity
- Particle size
- 20–60 µm whole conidia; fragments to <10 µm during thunderstorms
- Avoidance difficulty
- Very difficult
How Alternaria Allergy Presents
Symptoms by body system — useful for distinguishing Alternaria sensitivity from overlapping allergies and infections.
Respiratory
- Thunderstorm-triggered acute severe asthma (hallmark presentation in sensitized patients)
- Seasonal wheezing and chest tightness peaking July–September
- Allergic rhinitis with profuse watery discharge and nasal obstruction
- Chronic sinusitis and post-nasal drip during outdoor mold season
- Hypersensitivity pneumonitis in heavily exposed agricultural workers
Ocular
- Bilateral allergic conjunctivitis — itching, redness, tearing
- Chemosis (conjunctival swelling) during peak outdoor counts
- Periorbital edema following high mold-count afternoons
- Photophobia during acute allergic conjunctivitis flares
Dermal
- Contact urticaria from direct exposure to decaying vegetation
- Eczema flare in atopic-dermatitis patients during mold season
- Skin prick test wheal-flare — large local reactions common with standardized extracts
- Facial angioedema in rare severe systemic presentations
Systemic
- Severe asthma with fungal sensitization (SAFS) — refractory asthma driven by Alternaria IgE
- Exercise-induced bronchospasm worsened during high-count summer days
- Fatigue and cognitive fog correlating with outdoor mold-count peaks
- Anaphylaxis-like cardiovascular instability in thunderstorm asthma events (rare but documented)
Before I prescribe Alternaria shots, I always confirm rAlt a 1 sensitization by component testing. A patient positive on whole-extract Alternaria SPT who turns out to be Alt a 6-positive only may actually be primarily sensitized to Cladosporium — and those patients need a very different conversation. The Alt a 1 beta-barrel is the immunotherapy target; without confirming it, you may be treating the wrong mold.
When & Where Alternaria Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late July through September; counts reach 7,500 spores/m³ during dry, warm afternoons· ~12 weeks of clinically significant outdoor counts in temperate Northern Hemisphere
US Exposure Map
16 high-intensity statesWhat Alternaria Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Alternaria's major allergen Alt a 1 is unique — it has no homolog outside Pleosporaceae fungi — but two pan-fungal allergen families (enolase Alt a 6 and mannitol dehydrogenase Alt a 8) create meaningful cross-reactivity with Cladosporium and related molds.
Ulo c 1 shares 89% sequence identity with Alt a 1; U. chartarum formally reclassified as Alternaria chartarum (Woudenberg 2013)
Pleosporaceae family; Stm b allergen is ortholog of Alt a 1 with ~88% sequence identity
Alt a 8 / Cla h 8 mannitol dehydrogenase at 85.7% sequence identity; Alt a 6 / Cla h 6 enolase cross-reactive (79–94% identity)
Shared 17/26/43 kDa IgE-binding bands; 82% of Epicoccum-sensitized patients react to other fungi including Alternaria
Pleosporales order overlap; Epicoccum-Curvularia-Alternaria IgE cross-reactivity triangle documented in atopic panels
Is SCIT Right for Your Alternaria Allergy?
Answer five questions to see whether Alternaria allergy shots fit your clinical profile.
How severe are your Alternaria-season symptoms (late summer)?
The Alternaria SCIT Protocol
Alternaria SCIT follows the standard inhalant-allergen schedule, with one mandatory difference from pollen protocols: mold extracts must be vialed separately because Alt a 1 and fungal serine proteases degrade group-1 grass and ragweed allergens (AAAAI/ACAAI Practice Parameter, Cox 2011).
Starting from the most dilute vial, doses are increased incrementally each week until the target maintenance Alternaria dose is reached. With Curex's at-home SCIT protocol, your first injection and every dose increase are Zoom-supervised by the care team, each dose is followed by a 30-minute self-observation window with a prescribed epinephrine auto-injector confirmed on hand, and remaining build-up doses are self-administered at home. Cluster schedules (accelerated build-up over fewer weeks) are also available. Alt a 1 content varies by manufacturer — your allergist confirms the quantitation of the extract being used.
Once the target dose is reached, injection frequency decreases to monthly or every 2–4 weeks. Symptom scores typically begin improving in year 1 and reach maximum benefit by year 2–3 per Kuna 2011. Separate mold-only vials are maintained throughout — never mixed with pollen extracts.
Patients who complete 3–5 years of Alternaria SCIT may discontinue injections and retain durable symptom relief. Tabar 2019 JACI demonstrated significant reduction in skin reactivity after just 1 year of purified native Alt a 1 treatment, suggesting immunologic modification begins early. The decision to stop is individualized based on symptom control and allergist assessment.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Alternaria SCIT
Alternaria is the only mold allergen with multiple well-designed DBPC-RCTs demonstrating SCIT efficacy — a distinction shared by no other fungal allergen in clinical use.
- Combined symptom-medication score reduction (year 3)64%Kuna P et al., JACI 2011, 3-year DBPC SCIT in children, N=111
- Combined score reduction (year 2)39%Kuna P et al., JACI 2011, same cohort, year 2 interim
- Symptom + medication reduction (year 1 with purified Alt a 1)45%Tabar AI et al., JACI 2019, first DBPC RCT with native Alt a 1
- Off-label SCIT comparator improvement (3-year trial)97%Pozzan & Milani, Inflamm Allergy Drug Targets 2010, N=42 (comparator arm)
Two independent DBPC-RCTs (Kuna 2011, Tabar 2019) confirm that Alternaria SCIT produces clinically meaningful and statistically significant improvement in combined symptom-medication burden — a distinction no other mold allergen can claim. Individual patient outcomes depend on confirmed Alt a 1 sensitization, extract Alt a 1 content, and adherence to the 3–5 year course.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Alternaria SCIT Side Effects
Alternaria SCIT side effects follow the general inhalant-allergen safety profile, with the additional consideration that mold extracts contain serine proteases that must be kept in separate vials to prevent degradation of co-administered allergens.
Local reactions
4 documentedSystemic reactions
4 documentedIn the Kuna 2011 JACI trial, Alternaria SCIT was well tolerated with no severe systemic reactions requiring epinephrine at the 100 µg/mL equivalent dose. Mold extracts carry a slightly higher systemic-reaction surveillance rate than pollens; the 30-minute post-dose observation window is therefore non-negotiable. With Curex's at-home protocol, that window is self-observed with a prescribed epinephrine auto-injector confirmed on hand, while the first injection and every dose change are Zoom-supervised by your care team.
SCIT vs Alternatives for Alternaria
Patients with Alternaria allergy have four main management options, each with distinct trade-offs; SCIT is the only option with disease-modifying evidence specific to this mold.
| Criterion | SCITBest | At-Home SCIT Shots (Curex) | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | 63.5% score reduction (Kuna 2011) | Same disease-modifying mechanism as clinic SCIT; allergen candidacy confirmed by allergist | Partial — outdoor mold is nearly unavoidable | Symptom relief only — no disease modification |
| 5-yr cost | $3,500–$15,000 total | $129/month via Curex | Low | $500–$2,000/year |
| Duration | 3–5 years maintenance | 3–5 years typical | Ongoing lifestyle modification | Required every season indefinitely |
| Convenience | Weekly then monthly visits | Weekly self-injection at home; 30-min self-observation; no clinic trips during maintenance | Moderate burden — HEPA, humidity control | Daily pills/sprays |
| Safety | 30-min observation required | Low systemic risk with epinephrine kit + telehealth oversight | No injection risk | Generally safe; steroids have long-term risks |
| Lasting effect | 7–12+ years post-treatment | Full SCIT durability expected with completed course | No disease modification | Symptoms return when medication stops |
SCITBest
At-Home SCIT Shots (Curex)
Avoidance
Medications
SCIT is the only Alternaria-specific intervention with robust DBPC-RCT evidence for disease modification. Curex delivers that same disease-modifying SCIT — a personalized serum sterile-compounded to USP <797> standards — as weekly at-home self-injections at $129/month, with board-certified allergist oversight via telehealth, an epinephrine auto-injector prescribed and confirmed on hand before the first dose, and live Zoom-supervised dosing for the first injection and every dose change.
What Alternaria SCIT Actually Costs
Most major US insurers cover Alternaria SCIT under standard allergy-immunotherapy benefits when prescribed by a board-certified allergist with documented positive IgE testing; out-of-pocket costs depend on your deductible, co-insurance, and whether your provider is in-network. Confirm prior authorization requirements for extract preparation codes. Curex at-home IgE testing identifies specific alternaria sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
Flat monthly subscription — includes consult, prescription, and at-home dosing for sublingual immunotherapy.
See if you qualifyStop guessing about your alternaria allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Alternaria SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Alternaria is the only mold allergen with multiple published double-blind placebo-controlled randomized controlled trials (DBPC-RCTs) specifically studying SCIT. The Kuna 2011 JACI trial in children showed 63.5% combined symptom-medication score reduction at year 3. The Tabar 2019 JACI trial used purified native Alt a 1 and demonstrated significant benefit after just one year. No other mold species has reached this level of trial evidence. This is why international immunotherapy guidelines (AAAAI/ACAAI Practice Parameter, EAACI) recommend Alternaria SCIT for moderate-to-severe disease while stating that SCIT for other molds lacks sufficient evidence to recommend routinely.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.